Third Xiangya Hospital
中南大学湘雅三医院
Listed for 28 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Third Xiangya Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌19 papers led
- Hepatocellular carcinoma肝细胞癌41 papers led
- Stomach cancer胃癌17 papers led
- Lung cancer肺癌36 papers led1 open trial led
- Pancreatic cancer胰腺癌22 papers led1 open trial led
- Breast cancer乳腺癌36 papers led
- Glioma胶质瘤14 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤24 papers led
- Neuroblastoma神经母细胞瘤2 papers led
- Multiple myeloma多发性骨髓瘤19 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症6 papers led
- Lymphoma淋巴瘤12 papers led
- Haemophilia A血友病 A0 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Myasthenia gravis重症肌无力3 papers led
- Coronary heart disease冠心病9 papers led
- Congenital heart disease先天性心脏病3 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
- Pompe disease庞贝病0 papers led
- Behçet disease白塞病1 paper led
- Alport syndromeAlport 综合征0 papers led
- IgA nephropathyIgA 肾病4 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led
Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 19 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
6 hospitals in Changsha for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLDRT and Chemoimmunotherapy in NPC With Liver Metastasis
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06788002
Age 18 years to 70 years (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led19
- Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy.
- BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.
- Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma.
- PLUNC inhibits invasion and metastasis in nasopharyngeal carcinoma by inhibiting NLRP3 inflammasome activation.
- Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2.
- Neutrophil-to-lymphocyte ratio and monocyte-to-eosinophil ratio as prognostic indicators for advanced nasopharyngeal carcinoma.
- APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.
- TRAF4 regulates ubiquitination-modulated survivin turnover and confers radioresistance.
- MicroRNA-101-3p inhibits nasopharyngeal carcinoma cell proliferation and cisplatin resistance through ZIC5 down-regulation by targeting SOX2.
- Exosomes loaded with circPARD3 promotes EBV-miR-BART4-induced stemness and cisplatin resistance in nasopharyngeal carcinoma side population cells through the miR-579-3p/SIRT1/SSRP1 axis.
- circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.
- Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma.
- The immune escape mechanism of nasopharyngeal carcinoma.
- LncRNA SNHG1 promotes nasopharyngeal carcinoma development via targeting miR-424-5p.
- C2orf40 inhibits metastasis and regulates chemo-resistance and radio-resistance of nasopharyngeal carcinoma cells by influencing cell cycle and activating the PI3K/AKT/mTOR signaling pathway.
- Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma.
- Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis.
- Transcription factor STAT1 promotes the proliferation, migration and invasion of nasopharyngeal carcinoma cells by upregulating LINC01160.
- Reply: Diagnostic value of exosomal circMYC in radioresistant nasopharyngeal carcinoma: Methodological issues.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)4
- Bionic nanobombs target nasopharyngeal carcinoma to enhance the efficacy of chemoradiotherapy by destroying DNA damage repair systems
- Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
- Data from Epstein–Barr Virus–Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1
- The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 41 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Open trials led
- 0
- recruiting or about to
6 hospitals in Changsha for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led41
- Detection of macrotrabecular-massive hepatocellular carcinoma based on viscoelastic characteristics obtained by multifrequency magnetic-resonance elastography.
- MicroRNA-6069 ASO inhibits the growth of hepatocellular carcinoma by PLEKHO1.
- Analysis of influencing factors for achieving textbook outcome after laparoscopic right posterior sectionectomy of hepatocellular carcinoma.
- The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance.
- Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score matching and inverse probability weighting analysis.
- Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System.
- Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma.
- Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.
- Gene expression profile of anoikis reveals new subtypes of liver cancer and discovery of therapeutic targets and biomarkers.
- Exploration of safety indicators for radiotherapy in hepatocellular carcinoma: A real-world study.
- Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.
- SEH1L siliencing induces ferroptosis and suppresses hepatocellular carcinoma progression via ATF3/HMOX1/GPX4 axis.
- Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma.
- ZMAT2 condensates regulate the alternative splicing of TRIM28 to reduce cellular ROS accumulation, thereby promoting the proliferation of HCC cells.
- Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.
- Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
- Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain and RING finger domains protein 1 messenger RNA through recruiting eukaryotic
- Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma.
- ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.
- Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.
- PCMT1 is a potential target related to tumor progression and immune infiltration in liver cancer.
- A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort.
- The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model.
- Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma.
- Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
- CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.
- A novel approach for the analysis of single-cell RNA sequencing identifies TMEM14B as a novel poor prognostic marker in hepatocellular carcinoma.
- Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.
- Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
- CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis.
- Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
- SRSF10 stabilizes CDC25A by triggering exon 6 skipping to promote hepatocarcinogenesis.
- Circular RNA circ_GLIS2 suppresses hepatocellular carcinoma growth and metastasis.
- PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma.
- Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model.
- TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.
- Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis.
- Bcl-2 Associated Athanogene 2 (BAG2) is Associated With Progression and Prognosis of Hepatocellular Carcinoma: A Bioinformatics-Based Analysis.
- Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.
- Enhanced Chemodynamic Therapy and Chemotherapy via Delivery of a Dual Threat ArtePt and Iodo-Click Reaction Mediated Glutathione Consumption.
- Crosstalk between lncRNA DANCR and miR-125b-5p in HCC cell progression.
Chinese-language papers (not in the count)5
- SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.
- Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database.
- Effect of miRNA-200b on the proliferation of liver cancer cells via targeting SMYD2/p53 signaling pathway.
- Influence of different region of interest sizes on CT-based radiomics model for microvascular invasion prediction in hepatocellular carcinoma.
- [MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14].
All its trials on ClinicalTrials.gov, any status14
- Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
- TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Cancer
Stomach cancer
胃癌Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changsha for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingOGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05450835
Age 18 years to 75 years (registered criteria)
Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.
- AKR1B1 Inhibits Ferroptosis and Promotes Gastric Cancer Progression via Interacting With STAT3 to Activate SLC7A11.
- Circular RNA TFRC/SCD1 mRNA interaction regulates ferroptosis and metastasis in gastric cancer.
- Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.
- Metabolic reprogramming in Helicobacter pylori infection: from mechanisms to therapeutics.
- TRAF1 promotes the progression of Helicobacter pylori-associated gastric cancer through EGFR/STAT/OAS signalling.
- VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis.
- The expression signature, prognostic significance and immune cell infiltration of the OAS gene family in gastric cancer.
- Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer.
- LHPP promotes the intracellular reactive oxygen species accumulation and sensitivity of gastric cancer to cisplatin via JNK and p38 MAPK pathways.
- Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
- Comprehensive analysis of COMMD10 as a novel prognostic biomarker for gastric cancer.
- Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis.
- Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
- A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images.
- The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019.
- The impact of robotic technology on the learning curve for robot-assisted gastrectomy in the initial clinical application stage.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status3
Cancer
Lung cancer
肺癌Led 36 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.
6 hospitals in Changsha for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 13
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07138755
Age 18 years to 75 years (registered criteria)
Led by Third Xiangya Hospital; 1 listed hospital as study siteChangsha
- RecruitingctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06951646
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 12 listed hospitals as study sitesChangsha, Chongqing, Nanchang, Nanning, Shenyang, Taiyuan, Wuhan, Xinxiang
- RecruitingA Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07367529
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan
- RecruitingPropranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07886047
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha
- RecruitingPropranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07886229
Age 18 years to 75 years (registered criteria)
Led by Second Xiangya Hospital; 3 listed hospitals as study sitesChangsha
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingImmunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06840704
Age 18 years to Not stated (registered criteria)
Led by Hunan Cancer Hospital; 2 listed hospitals as study sitesChangsha
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- Not yet recruitingDiagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07882628
Age 18 years to 75 years (registered criteria)
Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led36
- Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real‑world multicenter retrospective study.
- Bilirubin nanoparticles modulate Treg/Th17 cells and functional metabolism of gut microbiota to inhibit lung adenocarcinoma.
- Daurisoline inhibits glycolysis of lung cancer by targeting the AKT-HK2 axis.
- Targeting MGST1 Makes Non-Small Cell Lung Cancer Cells Sensitive to Radiotherapy by Epigenetically Enhancing ALOX15-Mediated Ferroptosis.
- Spatial features of tumor-infiltrating lymphocytes in primary lesions of lung adenocarcinoma predict lymph node metastasis.
- Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
- Optimal dose-volume histogram thresholds for radiation pneumonitis prevention in lung cancer patients receiving immunotherapy.
- Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study.
- Targeting EGFR-Mcl-1 Axis by Piperlongumine as a Novel Strategy for Non-Small Cell Lung Cancer Therapy.
- Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.
- Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.
- Overexpression of transcription factor TBX5 inhibits the activation of YAP1-TEAD1 pathway to promote ferroptosis in lung cancer cells.
- Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
- S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.
- BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
- Survivin degradation by bergenin overcomes pemetrexed resistance.
- Gastrodin destabilizes survivin and overcomes pemetrexed resistance.
- Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway.
- Crosstalk between the lung microbiome and lung cancer.
- Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
- Construction and validation of a novel prognostic model of neutrophil‑related genes signature of lung adenocarcinoma.
- Comprehensive analysis of cuproptosis and copper homeostasis genotyping and related immune land scape in lung adenocarcinoma.
- Betulinaldehyde exhibits effective anti-tumor effects in A549 cells by regulating intracellular autophagy.
- Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.
- Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells.
- Preoperative Body Composition Combined with Tumor Metabolism Analysis by PET/CT Is Associated with Disease-Free Survival in Patients with NSCLC.
- Combined Microbiome and Metabolome Analysis Reveals a Novel Interplay Between Intestinal Flora and Serum Metabolites in Lung Cancer.
- Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma.
- An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
- Xanthohumol inhibits non-small cell lung cancer by activating PUMA-mediated apoptosis.
- MiR-3130-5p is an intermediate modulator of 2q33 and influences the invasiveness of lung adenocarcinoma by targeting NDUFS1.
- Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.
- Association between Sleep Traits and Lung Cancer: A Mendelian Randomization Study.
- Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
- The effects of the miR-21/SMAD7/TGF-β pathway on Th17 cell differentiation in COPD.
- Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status23
- The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
- ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
- Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
- Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
- Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
- A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
- A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
Cancer
Pancreatic cancer
胰腺癌Led 22 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.
5 hospitals in Changsha for pancreatic cancer192 hospitals in China for pancreatic cancer
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingA Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
- Phase
- Early phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07231094
Age 18 years to Not stated (registered criteria)
Led by Third Xiangya HospitalChangsha
- RecruitingAssociation Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07529626
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 2 listed hospitals as study sitesChangsha, Shanghai, Xi'an
- Not yet recruitingA Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07906691
Age 18 years to 45 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- MMP28 promotes tumorigenesis and gemcitabine resistance in pancreatic cancer by promoting glycolysis through interaction with SND1.
- Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.
- The miR-1305/KLF5 negative regulatory loop affects pancreatic cancer cell proliferation and apoptosis.
- Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021.
- Targeting SMYD2 promotes ferroptosis and impacts the progression of pancreatic cancer through the c-Myc/NCOA4 axis-mediated ferritinophagy.
- Clinical value of endoscopic ultrasound sound speed in differential diagnosis of pancreatic solid lesion and prognosis of pancreatic cancer.
- 24-Hour Urinary Sodium Excretion Is Associated With Increased Risk of Pancreatic Cancer: A Prospective Cohort Study.
- A retrospective comparative study on the treatment of non-metastatic pancreatic cancer using high-intensity focused ultrasound versus radical surgery.
- Contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) MASTER: A novel deep learning-based system in pancreatic mass diagnosis.
- The efficacy and safety of endoscopic ultrasound-guided fine-needle biopsy in gallbladder masses.
- Endoscopic ultrasound diagnosis system based on deep learning in images capture and segmentation training of solid pancreatic masses.
- Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer.
- DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.
- The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling.
- Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer.
- Primary pancreatic lymphoma diagnosed by endoscopic ultrasound-guided fine needle biopsy.
- Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study.
- Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
- Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.
- Comparison between modified wet suction and dry suction technique for endoscopic ultrasound-guided fine-needle biopsy in pancreatic solid lesions.
- Over-expressed RHEB promotes the progression of pancreatic adenocarcinoma.
- S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status6
- A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer
- Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.
- A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC
- A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
- Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
- 25G and 22G Puncture Needles
Cancer
Breast cancer
乳腺癌Led 36 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changsha for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07697443
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan
- Not yet recruitingClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Phase
- Phase 4
- Started
- 2023-10
- Posted
- Registry
- NCT05860907
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led36
- PAK2 promotes CTC cluster formation by phosphorylating E-cadherin to enhance cell-cell adhesion in breast cancer.
- Microplastics accumulated in breast cancer patients lead to mitophagy via ANXA2-mediated endocytosis and IL-17 signaling pathway.
- Potential role of CFLAR in enhancing 5-FU sensitivity and modulating immune cell infiltration in breast cancer.
- A prognostic model for basal-like breast cancer based on beta-alanine metabolism genes: EHHADH as a potential biomarker and target for drug screening.
- Probiotics prevent pegylated liposomal doxorubicin-associated hand-foot syndrome and oral mucositis of breast cancer patients following surgery and chemotherapy: a randomized placebo-controlled trial.
- Glycosylated protein-related microenvironmental features in breast cancer are associated with patient prognosis.
- The effects of emotional distress on the postoperative survival and progression in patients with breast cancer: a prospective observational study.
- The Usage of Mesh and Relevant Prognosis in Implant Breast Reconstruction Surgery: A Meta-analysis.
- Effects of dietary habits and catheterization type on breast cancer-related lymphedema: a retrospective cohort study.
- A comprehensive approach for evaluating lymphovascular invasion in invasive breast cancer: Leveraging multimodal MRI findings, radiomics, and deep learning analysis of intra- and peritumoral regions.
- Endocrine cancer trends 1990-2021: global disparities and health inequalities.
- POU2F2-mediated upregulation of lncRNA PTPRG-AS1 inhibits ferroptosis in breast cancer via miR-376c-3p/SLC7A11 axis.
- Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
- Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
- A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
- Platelet Membrane-Camouflaged Silver Metal-Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
- Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer.
- Global research trends and prospects related to tumor microenvironment within Triple Negative Breast Cancer: a bibliometric analysis.
- Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
- Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1.
- Erythrocyte membrane-camouflaged DNA-functionalized upconversion nanoparticles for tumor-targeted chemotherapy and immunotherapy.
- CPNE1 mediates glycolysis and metastasis of breast cancer through activation of PI3K/AKT/HIF-1α signaling.
- Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
- Copper homeostasis-associated gene PRNP regulates ferroptosis and immune infiltration in breast cancer.
- Optimism and symptoms of anxiety and depression among Chinese women with breast cancer: the serial mediating effect of perceived social support and benefit finding.
- miR-1290 modulates the radioresistance of triple-negative breast cancer by targeting NLRP3-mediated pyroptosis.
- Breast cancer combined with contralateral neck lymph node metastasis: a case report.
- Study of tRNA-Derived Fragment tRF-20-S998LO9D in Pan-Cancer.
- Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
- Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.
- Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model.
- Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis.
- Safety of Breast Cancer Mastoscopic Surgery from the Perspective of Immunity and Adipokines.
- Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis.
- Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance.
- Tumor microenvironment-responsive multifunctional nanoplatform based on MnFe2O4-PEG for enhanced magnetic resonance imaging-guided hypoxic cancer radiotherapy.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
- Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
Cancer
Glioma
胶质瘤Led 14 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led14
- Correlation between serum GFAP and 3-NT levels and the degree of neuronal injury in patients with glioma after surgery, and its diagnostic value.
- PLIN1 suppresses glioma progression through regulating lipid metabolism.
- HOXD8 drives Glioma progression through epithelial-mesenchymal transition regulation: Implications for prognosis and targeted therapy.
- CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
- PSMA2 promotes glioma proliferation and migration via EMT.
- Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.
- circPKD2 inhibits the glioma cell proliferation, invasion and glycolytic metabolism through regulating the miR-1278/LATS2 axis.
- High expression of six-transmembrane epithelial antigen of prostate 3 promotes the migration and invasion and predicts unfavorable prognosis in glioma.
- CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis.
- Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
- Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway.
- Early and Bi-hemispheric seizure onset in a rat glioblastoma Multiforme model.
- Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
- Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 24 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Changsha for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led24
- Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy.
- Single-cell analysis links DCUN1D5 to immune remodeling and cisplatin resistance in recurrent osteosarcoma.
- m6A methylation modification: Potential pathways to suppress osteosarcoma metastasis.
- Biopolymer-based bone scaffold for controlled Pt (IV) prodrug release and synergistic photothermal-chemotherapy and immunotherapy in osteosarcoma.
- Decoding the role of SLC25A5 in osteosarcoma drug resistance and CD8+ T cell exhaustion: The therapeutic potential of phyllanthin.
- Single-Atom Cu Nanozyme-Loaded Bone Scaffolds for Ferroptosis-Synergized Mild Photothermal Therapy in Osteosarcoma Treatment.
- The Targeted Therapies for Osteosarcoma via Six Major Pathways.
- RNA modification-related EIF4G2 is an immunotherapy determinant in osteosarcoma: A single-cell sequencing analysis.
- Identification of an ADME-related gene for forecasting the prognosis and responding to immunotherapy in sarcomas.
- Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma.
- METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m6 A-dependent manner.
- M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination.
- Bruceantinol targeting STAT3 exerts promising antitumor effects in in vitro and in vivo osteosarcoma models.
- Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma.
- Diverse cell death patterns-related signature for predicting prognosis and drug sensitivity of osteosarcoma patients.
- Antigen processing and presentation-related signature-derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation.
- Pan-cancer analysis shows that IBSP is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including osteosarcoma.
- Prognosis-related VDAC1 regulates the proliferation and apoptosis of osteosarcoma cells via the MAPK signaling pathway.
- Exosomal miR-181a-5p derived from SAOS-2 cells promotes macrophages M2 polarization by targeting RORA.
- RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma.
- A Targeted Erythrocyte Membrane-Encapsulated Drug-Delivery System with Anti-osteosarcoma and Anti-osteolytic Effects.
- Effect of the Notch1-mediated PI3K-Akt-mTOR pathway in human osteosarcoma.
- N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
- LncRNA-ROR/microRNA-185-3p/YAP1 axis exerts function in biological characteristics of osteosarcoma cells.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)14
- WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m6A-dependent manner.
- miR-485-5p/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K/AKT pathway.
- LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis.
- High SENP3 Expression Promotes Cell Migration, Invasion, and Proliferation by Modulating DNA Methylation of E-Cadherin in Osteosarcoma.
- Tanshinone I inhibits the growth and metastasis of osteosarcoma via suppressing JAK/STAT3 signalling pathway.
- Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma cell growth through the microRNA-181b/phosphatase and tensin homolog axis.
- miR-194 Suppresses Proliferation and Migration and Promotes Apoptosis of Osteosarcoma Cells by Targeting CDH2.
- miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.
- IL-1β-induced NF-κB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1.
- Primary osteosarcoma of frontal bone: A case report and review of literature.
- Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
- The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.
- [MicroRNA-150 inhibits osteosarcoma cell proliferation by targeting RUNX2 gene].
- [miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A].
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Changsha for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 19 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changsha for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led19
- Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma.
- Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.
- MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy.
- Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes.
- Exosomal tRF-1003 induces angiogenesis via regulating the HIF1α/VEGF signaling in multiple myeloma.
- Multiple myeloma exosomal miRNAs suppress cGAS-STING antiviral immunity.
- Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.
- Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
- BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
- The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.
- Exosomal miR-21-5p derived from multiple myeloma cells promote renal epithelial-mesenchymal transition through targeting TGF-β/SMAD7 signalling pathway.
- Pharmacokinetics, safety, and efficacy of GM1 ganglioside in healthy subjects and patients with multiple myeloma: Two dose-escalation studies.
- CD38-targeted and erythrocyte membrane camouflaged nanodrug delivery system for photothermal and chemotherapy in multiple myeloma.
- Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?
- IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.
- The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis.
- Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.
- tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma.
- Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Chinese-language papers (not in the count)4
- Clinical significance of CD45 and CD200 expression in newly diagnosed multiple myeloma patients.
- Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning.
- Diagnosis and treatment of multiple myeloma in Hunan Province.
- Research progress in proteasome inhibitor resistance to multiple myeloma.
All its trials on ClinicalTrials.gov, any status9
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Changsha for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status3
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 6 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led6
- Clinical Features, Treatment, and Outcomes of Nivolumab-Induced Hemophagocytic Lymphohistiocytosis.
- Biomarkers of pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis through single-cell transcriptomics.
- An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination.
- Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
- Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.
- Analysis of the clinical characteristics of lamotrigine-induced haemophagocytic lymphohistiocytosis.
Blood disorders
Lymphoma
淋巴瘤Led 12 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Changsha for lymphoma199 hospitals in China for lymphoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05768529
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led12
- Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.
- Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies.
- Challenges in Diagnosing Non-Nasal Natural Killer/T-Cell Lymphoma Mimicking Behçet Disease: A Case Report.
- Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
- CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
- Primary pancreatic lymphoma diagnosed by endoscopic ultrasound-guided fine needle biopsy.
- CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
- Identification of an individualized RNA binding protein-based prognostic signature for diffuse large B-cell lymphoma.
- Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
- Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma.
- Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma.
- Construction of biomimetic silver nanoparticles in the treatment of lymphoma.
All its trials on ClinicalTrials.gov, any status8
- Newly-diagnosed Pediatric T-cell ALL Protocol
- Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
- Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Blood disorders
Haemophilia A
血友病 ALed no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for haemophilia A132 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature.
- Hemizygous F8 p.G201E mutation identified in a Chinese family with haemophilia A.
- Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells.
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Changsha for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Myasthenia gravis
重症肌无力Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
All its trials on ClinicalTrials.gov, any status1
Other diseases
Coronary heart disease
冠心病Led 9 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for coronary heart disease231 hospitals in China for coronary heart disease
No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led9
- Association of psoriasis and genetic predisposition for the risk of cardiometabolic diseases: a population-based cohort study.
- EP300 improves endothelial injury and mitochondrial dysfunction in coronary artery disease by regulating histone acetylation of SOCS1 promoter via inhibiting JAK/STAT pathway.
- Genetic relationship between ageing and coronary heart disease: a Mendelian randomization study.
- Impact of white blood cell count on the development of contrast-induced acute kidney injury in patients receiving percutaneous coronary intervention.
- One-stop combined CT angiography of coronary and craniocervical arteries: recommended as the first examination for patients suspected of coronary or craniocervical artery disease.
- Multimorbidity and combined interventions for patients with coronary heart disease in Chinese population: Latent class analysis of a multi-center study.
- Identification of differentially expressed genes and the role of PDK4 in CD14+ monocytes of coronary artery disease.
- Single-nucleotide Polymorphism rs17860041 A/C in the Promoter of the PPIA Gene is Associated with Susceptibility to Kawasaki Disease in Chinese Children.
- 1H NMR-based metabolomics study of the dynamic effect of Xue-Fu-Zhu-Yu capsules on coronary heart disease rats induced by high-fat diet, coronary artery ligation.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status5
- Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
- Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
- The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
- Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)
Other diseases
Congenital heart disease
先天性心脏病Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led3
Chinese-language papers (not in the count)3
- [Development and validation of a risk prediction model for cryptogenic stroke secondary to patent foramen ovale in young people based on multimodal ultrasound].
- [Analysis of a child with Marfan syndrome due to a novel variant of FBN1 gene].
- A new ECG sign for sudden death: Transient prolonged QT interval following premature contraction.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Changsha for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led12
- A Rare TERT Mutation Associated with Idiopathic Pulmonary Fibrosis and COPD in a Chinese Family.
- Mefunidone treats pulmonary fibrosis by targeting SDH to regulate fibro-promoting macrophages.
- Identification of key mitochondria-related genes and their potential crosstalk role with immune pattern in Idiopathic pulmonary fibrosis.
- Succinate promotes pulmonary fibrosis through GPR91 and predicts death in idiopathic pulmonary fibrosis.
- Identification of the shared genes and immune signatures between systemic lupus erythematosus and idiopathic pulmonary fibrosis.
- Establishment and application of the BRP prognosis model for idiopathic pulmonary fibrosis.
- Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role.
- S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function.
- The Combined Model of CX3CR1-Related Immune Infiltration Genes to Evaluate the Prognosis of Idiopathic Pulmonary Fibrosis.
- Retrospective analysis of skin photosensitivity induced by pirfenidone.
- The networks of m6A-SARS-CoV-2 related genes and immune infiltration patterns in idiopathic pulmonary fibrosis.
- Investigation of a Hypoxia-Immune-Related Microenvironment Gene Signature and Prediction Model for Idiopathic Pulmonary Fibrosis.
All its trials on ClinicalTrials.gov, any status4
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- Exploring the Causal Association Between 91 Circulating Inflammatory Proteins and Neurodegenerative Diseases: A Bidirectional Two-Sample Mendelian Randomization and Bioinformatics Analysis.
- Genetic architecture of amyotrophic lateral sclerosis: a comprehensive review.
- Mendelian randomization study supports relative carbohydrate intake as an independent risk factor for amyotrophic lateral sclerosis.
- Analysis of SOD1 variants in Chinese patients with familial amyotrophic lateral sclerosis.
- Mutation analysis of MFSD8 in an amyotrophic lateral sclerosis cohort from mainland China.
Earlier papers (2016–2020)1
Other diseases
Pompe disease
庞贝病Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Changsha for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changsha for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Changsha for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Changsha for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study.
- Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model.
- Iron metabolism and chronic inflammation in IgA nephropathy.
- A Mendelian randomization study to assess the genetic liability of type 1 diabetes mellitus for IgA nephropathy.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status5
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- Atrasentan in Patients With IgA Nephropathy
- Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Changsha for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Changsha for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Getting in touch
Name card to show staff or a driver
中南大学湘雅三医院
Third Xiangya Hospital
长沙
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Third Xiangya Hospital of Central South University; Central South University Third Xiangya Hospital; Transplantation Center of the Third Xiangya Hospital; Third XiangYa Hospital; 中南大学湘雅三医院-门急诊楼